BioSpace News Archive

CRH Medical Corporation (the “Company”) (TSX: CRH) (NYSE MKT: CRHM), announces that Dr. Anthony Holler has advised the Company that he will resign as a member and Chair of the Board of Directors of the Company effective immediately in order to focus on other business matters.

Quanta, Inc. (QNTA: OTC) and Resonant Specific Technologies, Inc. announced a medical industry partnership today wherein Quanta will co-brand and supply its Muscle Rub to assist in reducing patient discomfort as an adjunct to treatment protocols that use RST-Sanexas neoGEN Electric Cell Signaling Treatment (EcST) devices in physician offices, clinics and hospitals to facilitate patient’s pain management and discomfort.

Zymergen Announces Acquisition of enEvolv, Accelerating Ability to Deliver High-Value Products to Market

Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ( www.oramed.com ), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced positive feedback from its initial End-of-Phase 2 (EoP2) meeting with the U.S. Food and Drug Administration (FDA) to discuss Chemistry Manufacturing a

Publicly available resource monitors development of therapies to treat and prevent disease

Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today provided guidance on their work to develop a peptide vaccine against the new coronavirus SARS-CoV-2 using the company’s proprietary and patented Ii-Key immune system activation technology.

OpGen, Inc., a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease, announced an update on shareholder proxy voting in relation to the business combination with Curetis.

Abbott will announce its first-quarter 2020 financial results on Thursday, April 16, 2020, before the market opens.

Medical Marijuana, Inc. (OTC: MJNA) (the “Company”), the first-ever publicly traded cannabis company in the United States that launched the world’s first-ever cannabis-derived nutraceutical products, brands and supply chain, announced today that its portfolio investment company Kannalife, Inc. (“Kannalife”) (OTCQB: KLFE) has been issued Australian Patent AU2015204609B2

Dragonfly Therapeutics, Inc. (“Dragonfly”), today announced an expansion of its strategic collaboration with Merck, known as MSD outside the United States and Canada to discover, develop and commercialize a number of Dragonfly’s candidate natural killer (“NK”) cell engager immunotherapies for oncology, infectious disease, and immune disorders.